Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

News & Events

Results from three HCRN studies presented at GU ASCO

Three Hoosier Cancer Research Network studies were featured in poster sessions during the 2017 Gastrointestinal Cancers Symposium, Feb. 16-18 in Orlando.

Read More

Ellis honored for commitment and compassion

Serving others has been a lifetime calling for Cara Ellis. As a child, her parents taught her to appreciate what she had and to make the most of every opportunity. “I remember my father saying that he would love for his children to do some type of work where we are helping others.’’ Ellis recalls.

Hoosier Cancer Research Network (HCRN) recently honored Ellis, a clinical research coordinator at IU Health Central Indiana Cancer Centers, with the Sandra Turner Excellence in Clinical Research Award.

Read More

HCRN seeks student interns

Hoosier Cancer Research Network (HCRN), a nonprofit cancer research organization in Indianapolis, is seeking graduate student interns for the 2017-2018 academic year. Training will be scheduled for May 2017.
 
Three internship positions are currently available: a communications internship and two general internships. All positions will require 20-25 hours per week on-site in our Indianapolis office. Read More

Ansari reflects on success and change in community oncology

In 1984, a small group of community-based oncologists and faculty members at the Indiana University Cancer Center came together with a shared mission: bring academic and community physicians together to develop cancer trials tailored to community needs. Thus, the Hoosier Cancer Research Network (formerly Hoosier Oncology Group) was founded.

Meet Rafat H. Ansari, M.D., F.A.C.P., a medical oncologist/hematologist at Michiana Hematology Oncology and one of the six founding members of Hoosier Cancer Research Network (HCRN). Before HCRN had ever set out into “infinite possibilities,” Ansari was there, laying the foundations of the future through the insight and resolve that are characteristic of the group.

Read More

HCRN chairman launches third “Reps” challenge

For the third consecutive year, Hoosier Cancer Research Network chairman Christopher A. Fausel, PharmD, is combining his passion for investigator-initiated research with his annual participation in the Arnold Sports Festival Pump & Run 5K in Columbus, Ohio.

Fausel has participated in the annual strength and endurance event for several years, and is inviting pledges in support of Hoosier Cancer Research Network (HCRN) for every bench press “rep” he completes (maximum of 30) during the event on Sunday, March 5, 2017. Read More

Study compares docetaxel with or without nivolumab in advanced non-small cell lung cancer

A new study led by researchers at the Indiana University Melvin and Bren Simon Cancer Center may help answer questions about the role of immunotherapy in combination with chemotherapy in treating lung cancer patients whose disease worsened after initial response to immunotherapy.

The randomized phase II study, known as HCRN LUN15-233, involves docetaxel (also known as Taxotere®) with or without nivolumab (also known as Opdivo®).

The study is now open to accrual at the Indiana University Melvin and Bren Simon Cancer Center. Additional sites will open the study in the near future. Nasser Hanna, MD, (pictured) is leading the study, along with co-investigators Laura Lourdes, MD; Shadia Jalal, MD; and Lawrence Einhorn, MD. Read More

Fisher honored for lifetime of service

For more than four decades, William B. Fisher, MD, a medical oncologist at the IU Health Ball Memorial Hospital Cancer Center, has served cancer patients, their families, and the community of East Central Indiana. Dr. Fisher was one of six oncologists who founded Hoosier Cancer Research Network (known then as the Hoosier Oncology Group) in the mid 1980s, and served as its founding vice chair. He has remained a strong supporter of the vision for collaborative research to expand patient access to clinical trials throughout the state of Indiana and beyond. In honor of his longstanding commitment, HCRN recently presented Dr. Fisher with the organization’s first-ever Lifetime Achievement Award during an event in Indianapolis. Read More

OncoGenex announces positive survival results for GU12-160 study

OncoGenex Pharmaceuticals, Inc. has announced positive survival results from the final analysis of the Phase 2 Borealis-2™ trial of apatorsen in combination with docetaxel treatment that enrolled 200 patients with metastatic bladder cancer whose disease had progressed following first-line platinum-based chemotherapy. The trial, also known as HCRN GU12-160, was conducted by the Hoosier Cancer Research Network at 28 sites across the United States.

Patients who received apatorsen treatment experienced a 20 percent reduction in risk of death, compared to patients receiving docetaxel alone (HR=.80; 80% CI: 0.65-0.98; p=0.078). The primary analysis was a superiority test of overall survival, performed at a one-sided 0.10 significance level using a stratified log-rank test.

Read more at oncogenex.com. Read More

Wayne joins HCRN Board of Directors

Hoosier Cancer Research Network (HCRN), a nonprofit cancer research organization in Indianapolis, recently welcomed Chris Wayne, vice president of oncology at Community Health Network, as a member of its Board of Directors.

A native Hoosier, Chris has about 25 years of experience in healthcare administration, mostly in oncology operations and strategic planning.

“I’ve been fortunate as an administrator to be responsible for mostly oncology throughout my career,” Wayne said. “My role as an administrator is to support our physicians, our nurses, and all those who are along the continuum of care.” Read More

HCRN study tests efficacy of supportive therapy with ginseng for patients receiving regorafenib

A new Hoosier Cancer Research Network study is evaluating whether ginseng can help lessen fatigue in patients treated with regorafenib.

The study, known as GI14-191, builds on earlier research that showed daily use of American ginseng significantly decreased the level of fatigue experienced by cancer patients undergoing treatment. GI14-191 focuses on patients receiving regorafenib for colorectal cancer. The study is currently open to accrual at Wake Forest Baptist Health in Winston-Salem, N.C., with additional sites expected to open in the near future. Read More

More News & Events →